CME Satellite Symposium

CLICK HERE TO LAUNCH ON-DEMAND PROGRAM

About the Program:

• Program Overview
• Program Agenda
• Target Audience
• Learning Objectives
• Faculty
• Accreditation Statement
• Credit Designation
• Disclosure of Conflicts of Interest
• Instructions for Participation and Credit
• Disclosure of Unlabeled Use
• Disclaimer

Program Overview:

We invite you to attend our live satellite symposium entitled, "The Evolving Landscape of HCV Treatment: Individualizing Care to Maximize SVR." This symposium will utilize patient case vignettes that describe the latest clinical information in this field and illustrate how to apply recent clinical findings to individual patients with CHC. Topics covered will include new treatment options for different HCV genotypes and difficult to treat populations, including those with various degrees of cirrhosis and chronic kidney disease. The outcome of this program will be that clinicians who treat patients with CHC will have an improved understanding of the various data supporting the optimal management of patients with CHC and will be able to apply this information in their clinical practices to improve patient care.

We look forward to your participation,
Nezam Afdhal, MD and Mark Sulkowski, MD
Program Co-Chairs

Program Agenda:

Target Audience:

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.

Back to Top

Learning Objectives:

After completing this activity, the participant should be better able to:

• Discuss the epidemiology of chronic hepatitis C (CHC) and identify populations at risk for CHC
• Follow national guidelines for testing and diagnosing people with CHC and link diagnosed patients with HCV infection to appropriate care
• Utilize current standards and guidelines for the individualized and optimal management of a variety of patients with CHC
• Discuss future medications and strategies in development for the treatment of patients with CHC and describe how these new options will impact their practice

• Release Date: December 30, 2015

  Expiration Date: December 30, 2016

  Estimated time to complete this program: 1 hour, 30 minutes 

  Media: Internet

Back to Top

Course Directors:

Nezam H. Afdhal, MD
	Professor of Medicine Harvard School of Medicine Chief of Hepatology, Director of Liver Center Beth Israel Deaconess Medical Center Boston, Massachusetts

Mark Sulkowski, MD
	Professor of Medicine and Medical Director Viral Hepatitis Center Johns Hopkins University School of Medicine Baltimore, Maryland

Faculty:

Paul Kwo, MD
	Professor of Medicine Medical Director, Liver Transplantation Division of Gastroenterology and Hepatology Indiana University School of Medicine Indianapolis, Indiana

Graham R. Foster, FRCP, PhD
	Professor of Hepatology The Liver Unit Consultant Hepatologist Queen Mary University of London London, United Kingdom

Norah A. Terrault, MD, MPH
	Professor of Medicine & Surgery Department of Medicine Director of Viral Hepatitis Research in Liver Transplantation University of California San Francisco San Francisco, California

Rafael Esteban, MD
	Head, Internal Medicine and Liver Unit Hospital Universitario Val d’Hebron Professor of Medicine Universidad Autonoma de Barcelona Barcelona, Spain

Stefan Zeuzem, MD
	Professor of Medicine and Chief Department of Medicine I J.W. Goethe University Hospital Frankfurt, Germany

Back to Top

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation:

The Postgraduate Institute for Medicine designates this The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest:

 

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to provideing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commerical interest. 

Nezam Afdhal, MD

• Consulting Fees: Merck, Gilead, Echosens, GSK, Ligand, Janssen, Riovant, Co-Crystal, Shionogi
• Research Support: Gilead, Abbvie, BMS
• Employee/Salary: Sprink Bank Pharmaceuticals
• Other: Director-TRIO Healthcare
• Stock: Allurion, Gilead, Sprink Bank Pharmaceuticals

• Consulting Fees: Gilead, AbbVie, Janssen, Merck

Graham R. Foster, FRCP, PhD

• Consulting Fees: Abbvie, BMS, Gilead, Merck, Janssen, GSK, Tekmira, Alnylam, Springbank, Roche
• Fees for Non-CME/CE Services: Abbvie, BMS, Gilead, Merck, Janssen, GSK, Tekmira, Alnylam, Springbank, Roche
• Contracted Research: Abbvie, BMS, Gilead, Merck, Janssen, GSK, Springbank, Roche

Paul Kwo, MD

• Consulting Fees: Abbvie, BMS, Janssen, Gilead, Merck
• Contracted Research: Abbvie, BMS, Janssen, Gilead, Merck

Norah A. Terrault, MD, MPH

• Consulting Fees: BMS, Achillion, Merck, Janssen, Gilead, Biotest
• Contracted Research: Gilead, Novartis, Biotest, Vertex, Abbvie

Stefan Zeuzem, MD

• Consulting Fees: Abbvie, BMS, Gilead, Janssen, Merck

Mark Sulkowski, MD

• Consulting Fees: Abbive, BMS, Janssen, Gilead, Merck
• Contracted Research: Achillion, Abbvie, BMS, Janssen, Gilead

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

The following PIM staff serve as clinical content reviewers and/or participate in planning CME/CE activities in a manner that may affect content:, Judi Smelker-Mitchek, RN, BSN; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Shultz, RN, MSN, CCMEP and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.

There are no fees for participating and receiving CME credit for this activity. During the period, December 30, 2015 through December 30, 2016, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on www.cmeuniveristy.com. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 10988.  Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately.  Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

Back to Top

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Back to Top